z-logo
open-access-imgOpen Access
Classification and Grading of Melanocytic Lesions in a Mouse Model of NRAS-driven Melanomagenesis
Author(s) -
CharlesAntoine Assenmacher,
Sara Francesca Santagostino,
Mark A. Oyama,
JeanChristophe Marine,
Elise Bonvin,
Enrico Radaelli
Publication year - 2020
Publication title -
journal of histochemistry and cytochemistry
Language(s) - English
Resource type - Journals
eISSN - 1551-5044
pISSN - 0022-1554
DOI - 10.1369/0022155420977970
Subject(s) - neuroblastoma ras viral oncogene homolog , microphthalmia associated transcription factor , grading (engineering) , immunohistochemistry , pathology , biology , medicine , cancer , transcription factor , gene , kras , ecology , biochemistry , colorectal cancer
The mouse line carrying the Tg(Tyr-NRAS*Q61K)1Bee transgene is widely used to model in vivo NRAS-driven melanomagenesis. Although the pathological features of this model are well described, classification and interpretation of the resulting proliferative lesions—including their origin, evolution, grading, and pathobiological significance—are still unclear and not supported by molecular and biological evidence. Focusing on their classification and grading, this work combines histopathology and expression analysis (using both immunohistochemistry [IHC] and quantitative PCR) of selected biomarkers to study the full spectrum of cutaneous and lymph nodal melanocytic proliferations in the Tg(Tyr-NRAS*Q61K)1Bee mouse. The analysis of cutaneous and lymph nodal melanocytic proliferations has demonstrated that a linear correlation exists between tumor grade and Ki-67, microphthalmia-associated transcription factor (MITF), gp100, and nestin IHC, with a significantly increased expression in high-grade lesions compared with low-grade lesions. The accuracy of the assessment of MITF IHC in melanomas was also confirmed by quantitative PCR analysis. In conclusion, we believe the incorporation of MITF, Ki-67, gp100, and nestin analysis into the histopathological classification/grading scheme of melanocytic proliferations described for this model will help to assess with accuracy the nature and evolution of the phenotype, monitor disease progression, and predict response to experimental treatment or other preclinical manipulations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom